Volume 5, Issue 1 (Avicenna Journal of Pharmaceutical Research 2024)
Avicenna J Pharma Res 2024, 5(1): 1-8 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nazari Dehkordi T, Sharifi F, Shabanian S. Comparison of the Controlling Effect of Uterine Contractions of "Isoxsuprine and Oral Magnesium Fort" With "Isoxsuprine" in Preterm Labor Prevention. Avicenna J Pharma Res 2024; 5 (1) :1-8
URL: http://ajpr1.umsha.ac.ir/article-1-23-en.html
URL: http://ajpr1.umsha.ac.ir/article-1-23-en.html
1- Department of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
2- Department of Midwifery, Faculty of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran & Department of Nursing and Midwifery, Kazerun branch, Islamic Azad University, Kazerun, Iran
3- Associate Professor of Gynecology and Obstetrics Department, Shahrekord University of Medical Sciences, Perinatology Fellowship, Shahrekord, Iran
2- Department of Midwifery, Faculty of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, Iran & Department of Nursing and Midwifery, Kazerun branch, Islamic Azad University, Kazerun, Iran
3- Associate Professor of Gynecology and Obstetrics Department, Shahrekord University of Medical Sciences, Perinatology Fellowship, Shahrekord, Iran
Abstract: (57 Views)
Background and Objective: Preterm labor is a significant challenge in obstetrics and gynecology. Various pharmacological agents have been explored for their ability to delay delivery and improve neonatal outcomes. This study aimed to compare the effectiveness of isoxsuprine alone versus a combination of oral magnesium fort and isoxsuprine in controlling uterine contractions and preventing preterm labor.
Methods: In this clinical trial, 100 pregnant women between 24 and 34 weeks of gestation with a history of uterine contractions were enrolled. Participants were randomly assigned to two groups: the intervention group received oral magnesium fort combined with isoxsuprine, while the control group received isoxsuprine alone. The treatment continued until 37 weeks of gestation. The primary outcome was the interval from contraction control to delivery, and the secondary outcome was the frequency of uterine contractions.
Results: Overall, women in the intervention group had a significantly more extended latency period from contraction control to delivery and experienced fewer uterine contractions compared to the control group (P < 0.05). In a subgroup analysis of women in their second pregnancy, the mean gestational age at delivery was 243.79 ± 13.90 days in the control group versus 256.17 ± 8.60 days in the intervention group, with a statistically significant difference (P = 0.004).
Conclusion: Combining oral magnesium fort with isoxsuprine appears to be more effective than isoxsuprine alone in prolonging gestation and reducing uterine contractions. Further studies with larger sample sizes are warranted to confirm these findings.
Methods: In this clinical trial, 100 pregnant women between 24 and 34 weeks of gestation with a history of uterine contractions were enrolled. Participants were randomly assigned to two groups: the intervention group received oral magnesium fort combined with isoxsuprine, while the control group received isoxsuprine alone. The treatment continued until 37 weeks of gestation. The primary outcome was the interval from contraction control to delivery, and the secondary outcome was the frequency of uterine contractions.
Results: Overall, women in the intervention group had a significantly more extended latency period from contraction control to delivery and experienced fewer uterine contractions compared to the control group (P < 0.05). In a subgroup analysis of women in their second pregnancy, the mean gestational age at delivery was 243.79 ± 13.90 days in the control group versus 256.17 ± 8.60 days in the intervention group, with a statistically significant difference (P = 0.004).
Conclusion: Combining oral magnesium fort with isoxsuprine appears to be more effective than isoxsuprine alone in prolonging gestation and reducing uterine contractions. Further studies with larger sample sizes are warranted to confirm these findings.
Type of Study: Research |
Subject:
General
Received: 2026/08/25 | Accepted: 2024/06/30 | Published: 2024/06/30
Received: 2026/08/25 | Accepted: 2024/06/30 | Published: 2024/06/30
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
